AUS
NZ
UK
CA
USA
IND
Highlights
- MindBio progresses landmark Phase 2B trials for depression and cancer-related anxiety, with a promising outlook.
- Company pioneers the use of microdoses of psychedelic medicines for at-home treatment of psychiatric disorders.
- Significant technological developments in AI and genetics set to revolutionize precision medicine and commercialization.
MindBio Therapeutics Corp. (CSE:MBIO), a clinical-stage biopharmaceutical company specializing in psychiatric medicine, has provided an exciting update on its groundbreaking clinical trial progress and innovative technology developments. The Company is advancing two pioneering Phase 2B trials for the treatment of Major Depressive Disorder (MDD) and cancer-related anxiety and depression, utilizing microdoses of psychedelic medicines.
These trials are the first of their kind in the world, and MindBio is leading the way with government-approved studies investigating the safe, at-home use of microdoses of psychedelic medicine, specifically MB22001, a self-titratable form of lysergic acid diethylamide (LSD). The Phase 2B trial for MDD involves 90 patients in a triple-blind, double-dummy, active placebo-controlled design, while the trial for cancer-related distress includes 40 patients suffering from advanced stage cancer and associated mental health challenges, including anxiety and depression. This trial is also a double-blind, placebo-controlled study, assessing MB22001 as an adjunct to Meaning-Centered Psychotherapy.
Both trials are due for completion in the third quarter of 2025 and have progressed significantly beyond their halfway points. Patient recruitment will resume in February after a brief holiday break. These trials follow the success of Phase 1 and Phase 2A studies, which met all primary and secondary endpoints. Notably, the Phase 2A trial demonstrated an impressive 72% anti-depressant response sustained six months after an 8-week treatment cycle, alongside improvements in sleep, including REM sleep, and overall mood and wellbeing.
MindBio’s pioneering approach involves patients self-administering sub-hallucinogenic microdoses of MB22001 at home, allowing them to carry on with their daily routines. This innovative, scalable treatment model represents a breakthrough in psychedelic medicine, offering the potential to bring these therapies to the community effectively and safely. With thousands of doses administered in clinical trials to date, MindBio is demonstrating the successful implementation of its treatment thesis.
In addition to the clinical advancements, MindBio has made significant discoveries, particularly in the fields of genetics and physiology. These findings, which stem from the company’s vast clinical trial data, are revealing new insights into the potential of treating patients at home with psychedelic medicine. The use of machine learning techniques and artificial intelligence to analyze the data has enabled MindBio to develop precision diagnostic tools, improving the ability to predict patient outcomes and refine treatment protocols.
The Company is also exploring commercialization opportunities for these unique technologies, which may have applications beyond the pharmaceutical industry. MindBio’s innovative approach to managing safety protocols and patient outcomes with a highly regulated substance is setting the stage for potential breakthroughs that could reshape the broader healthcare landscape.
Justin Hanka, CEO of MindBio, commented, “We are delighted in the progress of our trials to date and are excited by the technological developments in the Company that are showing a lot of promise and potential for scaling commercially. Developing a novel drug is a time-consuming process through multiple clinical trials, and we are excited that the Company is progressing well with these trials and also has the opportunity to apply its technology and discoveries to other verticals.”
